India has the highest number of HIV-infected adolescents in Asia, but little is known about their treatment outcomes. We assessed rates and factors associated with loss to follow-up (LTFU) and mortality among Indian adolescents.
Introduction
Globally, there were approximately 36.7 (34.0-39.8) million people living with HIV at the end of 2015 [1] . Of these, over 2.1 million were adolescents between the ages of 10 and 19 years. Adolescents account for about 6% of all people living with HIV (PLHIV) and 15% of new HIV infections. Since 2004, access to paediatric antiretroviral treatment (ART) has expanded worldwide, resulting in a substantial decline in mortality rates in HIV-infected children [2] . Consequently, this has led to more HIV-infected children surviving to adolescence [3, 4] .
Outside sub-Saharan Africa, India has the highest number of adolescents living with HIV [5] . According to Joint United Nations Programme on HIV/AIDS (UNAIDS) figures, 126 000 adolescents in India are HIV-infected [6] , translating to 60% of the adolescent HIV burden in South Asia. Adolescence is a time of transformation and experimentation [7] . This period is also marked by heightened self-consciousness and a need to conform to peer behaviour which contributes to increased vulnerability. Studies from Africa have shown that HIV-infected adolescents often disengage from HIV care, undermining conventional preventive and treatment strategies that rely on regular interactions with the health care system [7, 8] . Furthermore, studies from Uganda showed that mortality rates among adolescents were similar to that of adults at 6.7% [9] . However, little data are available on the risk of, and factors associated with, loss to follow-up (LTFU) and mortality in adolescents living with HIV in Asia. Understanding the reasons associated with LTFU and mortality in HIV-infected adolescents may provide opportunities to design specific interventions to improve retention in care and avert mortality. Using a large programmatic data set of HIV-infected adolescents, this study sought to determine rates of, and factors affecting, LTFU and mortality in western India.
Methods

Study design and population
This study was a retrospective review of programmatic data routinely collected at the ART centre of Byramjee Jeejeebhoy Government Medical College (BJGMC) and Sassoon General Hospitals (SGH), Pune, India. The BJGMC-SGH ART centre was established in 2004, and has over 36 000 registered HIV-infected patients (including HIV-infected children), with approximately 350 patients accessing care every day. For the purpose of this analysis, data for all HIV-infected adolescents (10-19 years old) starting treatment at the ART centre between May 2005 and August 2014 were used. BJGMC and Johns Hopkins University ethics committees approved the project.
Data variables and definitions
The standard procedure for data collection under the Indian HIV programme involves the use of a structured paper form, which is then transcribed into an electronic database. Data collected include demographic and clinical characteristics for each participant at registration and selected clinical characteristics at subsequent visits. We abstracted key available variables obtained at registration, for all adolescents. These included age, gender, mode of HIV acquisition, date of ART start, CD4 counts, World Health Organization (WHO) stage, place of residence, the latest ART regimen, treatment outcomes (LTFU and death) and information on whether they were transferred to another ART centre.
Loss to follow-up information was directly available from the database and no additional modifications were made to the definition. The National AIDS Control Organization (NACO), India's HIV programme, defines LTFU as missing more than three consecutive monthly visits [10] . As most baseline characteristics had been measured only at registration, we included only those adolescents whose time between registration at the ART clinic and ART start was not more than 6 months, to account for time-varying covariates (age, CD4 counts, WHO staging and residence). As CD4 counts under the Indian HIV programme are measured once every 6 months, we believe this to be an appropriate time to use, while also achieving a reasonable compromise between sample size and potential unmeasured confounders. Furthermore, we included only those adolescents who had not received ART prior to registry at the ART centre and had at least one subsequent follow-up visit following treatment initiation. Adolescents who started treatment after 31 May 2014 were excluded to allow sufficient time for the participant to be lost to follow-up, according to the definition. Tracing of all participants deemed lost to follow-up or transferred to another centre was attempted by making telephone calls to numbers that participants had provided at registration.
Statistical analyses
We used descriptive statistics to describe baseline characteristics by participant status (alive on treatment, lost to follow-up, died or transferred to another centre). For the person-time calculation, we considered the date of administrative censoring (31 August 2014) as the last date for all those who were alive and on treatment. The last available visit date was used as the last date for participants transferred to another centre or lost to follow-up. When available, we used the recorded death dates ascertained by family members of the deceased, or the last visit date was used as a surrogate for the death date. We included the time period only while the participant was an adolescent; that is, we did not include the person-time beyond age 19 years. If a participant was lost to follow-up, transferred to another centre or died after age 19 years, we considered such a participant to be alive at 19 years, and changed the status accordingly. The competing risks method as defined by Fine and Gray [11] was used for the calculation of subdistribution hazard ratios (SHRs), with death taken as the competing risk, for the LTFU analysis. Age and CD4 counts were categorized on the basis of published literature, sex on the basis of biological sex at birth, WHO stage on the basis of clinical presentation at registration and ART regimen on the basis of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used.
Approximations of distance of participant residence from the ART centre were made down to the neighbourhood, using Google Maps. We used the same covariates to assess for an association with mortality. However, as death precludes LTFU from occurring, a Cox proportional hazard model was fitted for mortality. Covariates associated with LTFU and/or death in the literature and those with univariate associations with P < 0.1 were included in multivariable models. Sensitivity analyses to test for the robustness of our 6-month assumption for time-varying covariates were performed by checking for the value and direction of estimates when the difference between registration and ART start date was varied between 1 and 12 months. Statistical significance was defined as a twosided P-value < 0.05. All analyses were performed using STATA version 14 (StataCorp, College Station, TX).
Results
Baselines characteristics
Of 717 Table 1 shows the overall characteristics of adolescents who were retained in care, lost to follow-up, died and transferred to another centre.
Cumulative incidence and rates of, and factors associated with, LTFU
The overall median duration of follow-up was 16.2 months (IQR: 6.3-44 months). Thirty-seven patients (9.2%) were lost to follow-up, contributing to a crude LTFU rate of 4.4 [95% confidence interval (CI) 3.2-6.0] per 100 personyears (PY). The median CD4 count was 158 cells/lL (IQR: 90-281 cells/lL) among those lost to follow-up compared with 182 cells/lL (IQR: 109-274 cells/lL) for those retained in care (P = 0.51). A higher proportion of male adolescents were lost to follow-up compared with female adolescents (P < 0.05) and a higher proportion of those who started ART between 2005 and 2009 were lost compared with those who started ART later (P < 0.05). The cumulative LTFU incidence at 1, 2, 4 and 6 years of follow-up from ART start was 6.2% (95% CI: 3.9-9.1%), 8 Cumulative incidence and rates of, and factors associated with, mortality Overall, 42 (10.4%) adolescents died, contributing to a crude mortality rate of 4.9 per 100 person-years (95% CI: 3.7-6.7 per 100 person-years). Thirty (71.4%) were male and the median age at death was 12.3 years (IQR: 11.1-16.1 years). Adolescents who died were younger (P < 0.05) and had lower median CD4 counts 126 [IQR: 41-223] cells/ lL, compared with those retained in care 182 (IQR: 109-274), respectively; P < 0.05. The cumulative mortality incidence at 1, 2, 4 and 6 years of follow-up after ART start was 9.4% (95% CI: 6.7-13.1%), 11.7% (95% CI: 8.6-15.9%), 15.2% (95% CI: 10.9-20.8%) and 17.9% (95% CI: 12.7-24.8%), respectively (Fig. 2) .
In univariate analysis, an increase in CD4 count by 100 cells/lL (HR 0.68; 95% CI: 0.50-0.92), usage of efavirenz-based NNRTI regimens (HR 2.09; 95% CI: 1.12-3.93) and WHO stage III and IV (HR 2.54; 95% CI: (Table 3 ).
Discussion
Our study is among the first to describe a largely perinatally infected adolescent cohort receiving standard of care in a large public sector ART centre in India, the country with the third largest burden of HIV in the world [12] . Notably, we observed that adolescents had a low CD4 count and by 6 years in care the LTFU rate was 15% and the mortality rate was 18%. Furthermore, we identified older adolescents (15-19 years old) to be at the highest risk of LTFU and not surprisingly those with the most advanced clinical stage to be at the highest risk of mortality. Clearly, with one-third of the cohort being lost to follow-up or dying by 6 years despite ART initiation, more attention and resources are needed to reduce LTFU and death in this vulnerable population of youth. A wide range of LTFU rates (4.8-14.7 per 100 PY) have been reported from sub-Saharan Africa and our rates fall below this range [13] [14] [15] [16] . However, compared with these cohorts, which were chiefly female (52-66% female), our cohort had a higher proportion of male adolescents. As HIV-infected men have been shown to be more likely to be lost to follow-up [17] , our finding of low LTFU rates in a predominantly male cohort necessitates further investigation of cultural and behavioural differences between male adolescents in our cohort and their subSaharan counterparts in future studies.
As has been seen in adults, our cumulative LTFU incidence increased with longer follow-up [18, 19] . This can One person categorized as lost to follow-up had one value missing for the aforementioned variables, and hence the total number lost to follow-up for these three variables is 36. Continuous CD4 count per 100 cells/lL increase did not appear to be associated with loss to follow-up and the interpretation remained the same as when using categorical CD4 counts. Hence this has not been shown separately.
be explained by our observation that older adolescents aged 15-19 years were more likely to be lost to followup [13, 20] . We hypothesize that a number of synergistic factors contribute to this observation. Firstly, the fear of social ostracization, resulting from greater awareness of the stigmatization around HIV in late adolescence, could negatively impact attendance at an ART centre [21] . Secondly, this period is associated with sexual debut for some adolescents; [7] apprehension about inadvertent partner disclosure, if seen at the ART centre, along with reduced adult supervision, could further limit follow-up [22] . Lastly, the transition into adulthood may be associated with greater familial responsibilities for some adolescents, relegating personal health to a secondary priority [23, 24] . Greater access to social protection and providing adolescents with cash or kind benefits during their in person follow-ups, could be considered in order to improve retention among older adolescents [25, 26] .
The mortality rate in our cohort is higher than the mortality rate reported in some studies from South Africa [9, 13, 15] and was observed to be higher in the first few years after starting ART. Late presentation to care, as characterized by > 45% of adolescents presenting with either WHO stage III or IV disease, and nonavailability of regular viral load testing to optimize treatment regimens could be reasons for the high mortality rates observed. However, in more recent years, there has been a promising trend in the proportion of adolescents presenting much earlier (Fig. S1 ). In this regard, NACO's efforts in increasing HIV awareness among adolescents through its Adolescent Education Program [27] should be commended and its wider expansion championed.
Our study relied on programmatic data, and thus was limited by incompletely collected data on status of caregivers, adherence to ART and cause of death. Also, although only one-fifth of the adolescents self-reported behavioural acquisition of HIV infection, it is possible that responses were biased by social desirability, consequently providing an underestimate of the proportion of adolescents who were behaviourally infected. Furthermore, the data collected are from an urban centre catering to surrounding semi-urban and rural areas and may not be representative of all HIV-infected adolescents in India. Unavailability of routinely collected viral loads, under the Indian HIV programme, also precluded us from making associations between viral suppression and the treatment outcomes under consideration. Finally, although telephonic tracing of all individuals lost to follow-up and transferred to other centres was attempted, contact was established with only 23% of them or their relatives, limiting our ability to make reasonable estimates of the actual mortality rates for those lost to follow-up and transferred out (Figs S2 and S3). It is therefore conceivable that mortality rates are actually higher than those we have reported.
Over the past decade, India has rapidly rolled out ART to all children and adolescents and has established several ART centres, limiting LTFU as a consequence of distance and providing easy access to ART. Our report highlights the success of this effort, in that > 36% of the adolescents were transferred out to different ART centres in the region. However, despite these advances, we demonstrate that a third of HIV-infected adolescents who started ART had either been lost to follow-up or died by the 6th year of follow-up, representing a huge loss of an economically and socially productive group. Our report also brings to light a small group of adolescents who are unaware of their mode of HIV acquisition. While the exact mechanisms for this unawareness are difficult to comment upon, a primary driver could be nondisclosure of HIV status, as reported in a previous study from our group [28] . The existence of such a group brings to the forefront the necessity of discourse regarding disclosure guidelines in India.
With demographic transition and improvements in HIV care occurring hand in hand in India, it is more crucial now than ever to sensitize health care workers to adolescent-specific needs. Along with this, improvements in counselling and support services for older adolescents incorporating destigmatization mitigation techniques and close monitoring of adolescents with advanced clinical disease are some strategies that could benefit this vulnerable population. Future longitudinal studies should confirm our study findings.
